Database Query Results : Gemcitabine (Gemzar), ,

GEM, Gemcitabine (Gemzar): Click to Expand ⟱
Features: Chemo
GEM An IV antimetabolic antineoplastic used with cisplatin for inoperable non-small cell lung CA
Treats cancer of pancreas, lung, ovary and breast.

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Inhibition of DNA synthesis (antimetabolite effect) Incorporated into DNA → chain termination Normal dividing cells affected (bone marrow, GI epithelium) P, R, G Direct cytotoxicity Gemcitabine (2′,2′-difluorodeoxycytidine, dFdC) is phosphorylated to the triphosphate form (dFdCTP) which competes with dCTP, gets incorporated into DNA, and blocks DNA chain elongation.
2 Ribonucleotide reductase (RNR) inhibition dFdCDP inhibits RNR → deoxynucleotide pool depletion ↔ (normal proliferating cells also impacted) R, G Nucleotide pool imbalance Gemcitabine diphosphate (dFdCDP) inhibits RNR, reducing available dNTPs and enhancing the chain-termination effect.
3 Apoptosis induction (DNA damage response) DNA damage signaling → caspase activation Toxicity in dividing normal tissues G Execution of cell death Prolonged DNA synthesis arrest and replication stress triggers apoptosis pathways via ATR/Chk1, p53, and caspase cascades.
4 Cell-cycle arrest (S-phase accumulation) S-phase arrest steers cells into apoptosis ↔ G Cytostasis → death Accumulation of stalled replication forks enforces S-phase arrest and amplifies cytotoxicity.
5 DNA damage response signaling (ATR/Chk1/Chk2) Checkpoint activation ↔ R, G Damage signaling Replication stress activates ATR/Chk1/Chk2 and modulates cell-cycle checkpoints and repair responses.
6 NF-κB pro-survival signaling (resistance axis) NF-κB activation can reduce sensitivity ↔ R, G Resistance/modulation In some tumor models, NF-κB and other pro-survival axes mediate resistance to gemcitabine cytotoxicity; inhibition sensitizes cells.
7 Autophagy modulation (response to stress) Autophagy ↑ in some contexts (cytoprotective) ↔ G Adaptive stress response Gemcitabine can induce autophagy as a survival mechanism in some models; autophagy inhibition can sensitize cells in combination studies.
8 Reactive oxygen species (ROS) elevation (indirect) ROS ↑ (reported in some models) ↔ G Stress amplification Some preclinical studies report ROS increases secondary to replication stress; not a primary mechanism but modulates cell-death pathways.
9 Clinical resistance mechanisms (CDA, nucleoside transporters) CDA ↑; hENT1 ↓ correlates with resistance — G Resistance / exposure constraint Cytidine deaminase (CDA) inactivates gemcitabine; lower hENT1 transport reduces uptake — major clinical resistance factors.
10 Bioavailability / pharmacokinetics (IV dosing; systemic exposure) IV infusion achieves systemic levels ↔ — PK constraint Gemcitabine is given systemically (often IV) and achieves cytotoxic blood levels; rapid deamination by CDA and short half-life shape dosing.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (rapid biochemical activation / early metabolic engagement)
  • R: 30 min–3 hr (acute nucleotide pool effects / checkpoint signaling)
  • G: >3 hr (DNA damage response, cell death, phenotype outcomes)
Scientific Papers found: Click to Expand⟱
397- AgNPs,  GEM,    Silver nanoparticles enhance the apoptotic potential of gemcitabine in human ovarian cancer cells: combination therapy for effective cancer treatment
- in-vitro, Ovarian, A2780S
P53↑, P21↑, BAX↑, Bak↑, Cyt‑c↑, Casp3↑, Casp9↑, Bcl-2↓, ROS↑, MMP↓,
1158- And,  GEM,    Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer
TumCP↓, TumCCA↑, Apoptosis↑, STAT3↓, Akt↓, P21↑, BAX↑, cycD1/CCND1↓, cycE/CCNE↓, survivin↓, XIAP↓, Bcl-2↓, eff↑,
1362- Ash,  GEM,    Synergistic Inhibition of Pancreatic Cancer Cell Growth and Migration by Gemcitabine and Withaferin A
- in-vitro, PC, PANC1 - in-vitro, PC, Hs766t
ChemoSen↑, ROS↑, Apoptosis↑, TumCMig↓, F-actin↓, YMcells↓, NF-kB↓,
5385- AsP,  GoldNP,  GEM,    Development of ascorbyl palmitate based hydrophobic gold nanoparticles as a nanocarrier system for gemcitabine delivery
- in-vitro, BC, NA
ROS↑, Fenton↑, BioAv↑, EPR↑,
2750- BetA,  GEM,    Betulinic acid, a major therapeutic triterpene of Celastrus orbiculatus Thunb., acts as a chemosensitizer of gemcitabine by promoting Chk1 degradation
- in-vitro, PC, Bxpc-3 - in-vitro, Lung, H1299
CHK1↓, ChemoSen↑, tumCV↓, Apoptosis↑, DNAdam↑,
1110- EA,  GEM,    Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters
- vitro+vivo, Bladder, NA
TGF-β↓, SMAD2↓, SMAD3↓, SMAD4↓,
688- EGCG,  GEM,    Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial–Mesenchymal Transition: Enhanced Efficacy When Combined with Gemcitabine
- in-vitro, PC, NA
Zeb1↓, β-catenin/ZEB1↓, Vim↓, Akt↓, p‑IGFR↓, TumCG↓, TumCMig↓, TumCI↓,
810- GAR,  GEM,    Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures
- in-vitro, PC, NA
TumCP↓, Apoptosis↑, PARP↝, VEGF↝, MMPs↝, Casp↝, NF-kB↝, miR-21↝,
813- GAR,  GEM,    Dietary Garcinol Arrests Pancreatic Cancer in p53 and K-ras Conditional Mutant Mouse Model
- in-vivo, PC, NA
TumCG↓, OS↑,
5390- GoldNP,  GEM,  AsP,    Optimizing Gold Nanoparticles for Combination Therapy: Development of Hydrophobic Nanomedical Devices with Gemcitabine and Ascorbyl Palmitate
- in-vitro, BC, 4T1
EPR↑, eff↑,
2387- MET,  GEM,    Metformin Increases the Response of Cholangiocarcinoma Cells to Gemcitabine by Suppressing Pyruvate Kinase M2 to Activate Mitochondrial Apoptosis
- in-vitro, CCA, HCC9810
eff↑, tumCV↓, TumCMig↓, TumCI↓, Apoptosis↑, PKM2↓, PDHB↓,
1434- SFN,  GEM,    Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity
- in-vitro, CCA, HuCCT1 - in-vitro, CCA, HuH28 - in-vivo, NA, NA
HDAC↓, ac‑H3↑, ChemoSen↑, tumCV↓, TumCP↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, TumCI↓, VEGF↓, VEGFR2↓, Hif1a↓, eNOS↓, EMT?, TumCG↓, Ki-67↓, TUNEL↑, P21↑, p‑Chk2↑, CDC25↓, BAX↑, *ROS↓, NQO1?,
5102- SK,  GEM,    Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway
TumCG↓, ChemoSen↑, NF-kB↓, PCNA↓, Ki-67↓, p‑EGFR↓, ROS↑, TumCCA↑, P53↑, JNK↑, Akt↓,
5084- SSE,  GEM,    The Antitumor Activity of Sodium Selenite Alone and in Combination with Gemcitabine in Pancreatic Cancer: An In Vitro and In Vivo Study
- in-vitro, PC, PANC1 - vitro+vivo, PC, Panc02
tumCV↓, ChemoSen↑, TumCG↓, OS↑, MMP↓, AIF↑, GSH↓, Trx↓, ROS↑, AntiTum↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 14

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Fenton↑, 1,   GSH↓, 1,   NQO1?, 1,   ROS↑, 5,   Trx↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 1,   CDC25↓, 1,   MMP↓, 2,   XIAP↓, 1,  

Core Metabolism/Glycolysis ⓘ

PDHB↓, 1,   PKM2↓, 1,  

Cell Death ⓘ

Akt↓, 3,   Apoptosis↑, 6,   Bak↑, 1,   BAX↑, 3,   Bcl-2↓, 2,   Casp↝, 1,   Casp3↑, 1,   cl‑Casp3↑, 1,   Casp9↑, 1,   p‑Chk2↑, 1,   Cyt‑c↑, 1,   JNK↑, 1,   survivin↓, 1,   TUNEL↑, 1,  

Transcription & Epigenetics ⓘ

ac‑H3↑, 1,   miR-21↝, 1,   tumCV↓, 4,   YMcells↓, 1,  

DNA Damage & Repair ⓘ

CHK1↓, 1,   DNAdam↑, 1,   P53↑, 2,   PARP↝, 1,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   cycE/CCNE↓, 1,   P21↑, 3,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State ⓘ

EMT?, 1,   HDAC↓, 1,   p‑IGFR↓, 1,   STAT3↓, 1,   TumCG↓, 5,  

Migration ⓘ

F-actin↓, 1,   Ki-67↓, 2,   MMPs↝, 1,   SMAD2↓, 1,   SMAD3↓, 1,   SMAD4↓, 1,   TGF-β↓, 1,   TumCI↓, 3,   TumCMig↓, 3,   TumCP↓, 3,   Vim↓, 1,   Zeb1↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

p‑EGFR↓, 1,   eNOS↓, 1,   EPR↑, 2,   Hif1a↓, 1,   VEGF↓, 1,   VEGF↝, 1,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling ⓘ

NF-kB↓, 2,   NF-kB↝, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   ChemoSen↑, 5,   eff↑, 3,  

Clinical Biomarkers ⓘ

p‑EGFR↓, 1,   Ki-67↓, 2,  

Functional Outcomes ⓘ

AntiTum↑, 1,   OS↑, 2,  
Total Targets: 72

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

ROS↓, 1,  
Total Targets: 1

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:84  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page